Report Shows Growing Provider Acceptance, Understanding of Biosimilars

The U.S. biosimilars market is a dynamic and ever-evolving space, and a recent report shows growing acceptance of the medications among providers. Last year saw a handful of milestones related to these agents, and this year, particularly with the launches of biosimilars of AbbVie Inc.’s Humira (adalimumab), is likely to continue the trend, according to a recent report from Cardinal Health.

Titled 2023 Biosimilars Report: tracking market expansion and sustainability amidst a shifting industry, the report is based on responses to web-based surveys conducted in 2022 from both community- and hospital-based practices. Providers were from “therapeutic areas with the most potential for disruption in the year ahead.” Cardinal Health polled more than 100 rheumatologists in July and August, 125 dermatologists in September, 70 gastroenterologists in September and October, and 60 retina specialists in September and October.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

a-patient-getting-insulin-injection
February 16

Amjevita, First Biosimilar of Humira, Launches With Two-Tiered Pricing Strategy

Read More
a-patient-taking-pills
February 9

2023 Outlook: Humira Is Not Only Specialty Drug With Anticipated Biosimilars

READ MORE
scientist-holding-a-tube
January 12

2022 Saw Continued Approvals, Uptake of Biosimilars

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today